2 Information about sparsentan

Marketing authorisation indication

2.1

Sparsentan (Filspari, Vifor) is indicated for 'the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥ 1.0 g/day (or urine protein-to-creatinine ratio ≥ 0.75 g/g)'.

Dosage in the marketing authorisation

Price

2.3

The list price for sparsentan is £3,401.71 per 30‑pack of 200 mg tablets or £3,401.71 per 30‑pack of 400 mg tablets (excluding VAT; company submission).

2.4

The company has a commercial arrangement. This makes sparsentan available to the NHS with a discount. The size of the discount is commercial in confidence.